TPH1 and Cowden syndrome 1: In March 2017, telotristat ethyl was the first-in-class, small-molecule, peripheral TPH-1 inhibitor, which does not cross the blood–brain barrier, to be approved by the FDA for the management of CS-related diarrhea refractory to somatostatin analogs.